Loading clinical trials...
Loading clinical trials...
A Phase II Randomized Study For Patients With Muscle-Invasive Bladder Cancer Evaluating Transurethral Surgery And Concomitant Chemoradiation By Either BID Irradiation Plus 5-Fluorouracil And Cisplatin Or QD Irradiation Plus Gemcitabine Followed By Selective Bladder Preservation And Gemcitabine/Cisplatin Adjuvant Chemotherapy
Conditions
Interventions
induction cisplatin
induction 5-fluorouracil
+12 more
Locations
11
United States
Georgia Cancer Center for Excellence at Grady Memorial Hospital
Atlanta, Georgia, United States
Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
Boise, Idaho, United States
Cancer Institute at St. John's Hospital
Springfield, Illinois, United States
Parkview Regional Cancer Center at Parkview Health
Fort Wayne, Indiana, United States
St. Agnes Hospital Cancer Center
Baltimore, Maryland, United States
Start Date
December 1, 2008
Primary Completion Date
February 18, 2018
Completion Date
May 20, 2022
Last Updated
June 15, 2022
NCT03375307
NCT07061964
NCT04235764
NCT00026884
NCT07050771
NCT04585750
Lead Sponsor
Radiation Therapy Oncology Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions